Beacon Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Beacon Pharmaceuticals has been growing earnings at an average annual rate of 26.2%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 14.3% per year. Beacon Pharmaceuticals's return on equity is 10.5%, and it has net margins of 7%.
Key information
26.2%
Earnings growth rate
26.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | 14.3% |
| Return on equity | 10.5% |
| Net Margin | 7.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Beacon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9,402 | 662 | 3,427 | 0 |
| 30 Sep 23 | 8,812 | 651 | 3,199 | 0 |
| 30 Jun 23 | 8,510 | 510 | 3,291 | 0 |
| 31 Mar 23 | 8,190 | 699 | 2,669 | 0 |
| 31 Dec 22 | 7,887 | 936 | 2,427 | 0 |
| 30 Sep 22 | 7,774 | 812 | 2,529 | 0 |
| 30 Jun 22 | 8,023 | 935 | 2,499 | 0 |
| 31 Mar 22 | 6,976 | 936 | 2,280 | 0 |
| 31 Dec 21 | 7,733 | 1,170 | 2,316 | 0 |
| 30 Sep 21 | 7,839 | 1,158 | 2,347 | 0 |
| 30 Jun 21 | 7,121 | 863 | 2,307 | 0 |
| 31 Mar 21 | 7,719 | 1,007 | 2,748 | 0 |
| 31 Dec 20 | 6,493 | 603 | 2,669 | 0 |
| 30 Sep 20 | 5,797 | 396 | 2,618 | 0 |
| 30 Jun 20 | 5,591 | 381 | 2,533 | 0 |
| 31 Mar 20 | 5,368 | 115 | 2,254 | 0 |
| 31 Dec 19 | 5,155 | 104 | 2,184 | 0 |
| 30 Sep 19 | 4,919 | 121 | 2,057 | 0 |
| 30 Jun 19 | 4,647 | 118 | 1,959 | 0 |
| 31 Mar 19 | 4,564 | 176 | 1,885 | 0 |
| 31 Dec 18 | 4,281 | 162 | 1,717 | 0 |
| 30 Sep 18 | 3,917 | 142 | 1,573 | 0 |
| 30 Jun 18 | 3,761 | 126 | 1,566 | 0 |
| 31 Mar 18 | 3,295 | 122 | 1,376 | 0 |
| 31 Dec 17 | 3,259 | 118 | 1,378 | 0 |
| 30 Sep 17 | 3,082 | 114 | 1,301 | 0 |
| 30 Jun 17 | 2,948 | 104 | 1,200 | 0 |
| 31 Mar 17 | 3,004 | 89 | 1,168 | 0 |
| 31 Dec 16 | 2,764 | 67 | 1,082 | 0 |
| 30 Sep 16 | 2,640 | 63 | 1,030 | 0 |
| 30 Jun 16 | 2,492 | 61 | 937 | 0 |
| 31 Mar 16 | 2,279 | 58 | 817 | 0 |
| 31 Dec 15 | 2,169 | 58 | 760 | 0 |
| 30 Sep 15 | 2,128 | 43 | 732 | 0 |
| 30 Jun 15 | 2,053 | 39 | 708 | 0 |
| 31 Mar 15 | 2,085 | 32 | 728 | 0 |
| 31 Dec 14 | 1,970 | 27 | 662 | 0 |
| 30 Sep 14 | 1,898 | 25 | 624 | 0 |
| 30 Jun 14 | 1,690 | 24 | 555 | 0 |
| 31 Mar 14 | 1,502 | 11 | 527 | 0 |
| 31 Dec 13 | 1,482 | 12 | 546 | 0 |
| 30 Sep 13 | 1,309 | 9 | 476 | 0 |
| 30 Jun 13 | 1,227 | 9 | 409 | 0 |
Quality Earnings: BEACONPHAR has high quality earnings.
Growing Profit Margin: BEACONPHAR's current net profit margins (7%) are lower than last year (11.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BEACONPHAR's earnings have grown significantly by 26.2% per year over the past 5 years.
Accelerating Growth: BEACONPHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BEACONPHAR had negative earnings growth (-29.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.6%).
Return on Equity
High ROE: BEACONPHAR's Return on Equity (10.5%) is considered low.